trending Market Intelligence /marketintelligence/en/news-insights/trending/z1rFEjtMoMQ76MGsH33nlw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

ImmunoPrecise to acquire U-Protein for €6.8M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ImmunoPrecise to acquire U-Protein for €6.8M

ImmunoPrecise Antibodies Ltd. acquired all of U-Protein Express BV's issued and outstanding shares for €6.8 million.

ImmunoPrecise will pay €2.7 million in cash, issue €2 million of its shares and settle the remaining €2 million over a three-year period, either in cash or stock.

Martin Hessing, one of the principal shareholders of U-Protein, will join the ImmunoPrecise board.

ImmunoPrecise recently upsized a private placement to use the proceeds for the acquisition of U-Protein.